Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nabi completes enrollment in nicotine addiction study
Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007. “The
Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007. “The
Patients administered 4975 have not responded to the current treatments such as such as foot pads, non-steroidal anti-inflammatory drugs and injections of corticosteroids and would otherwise had the
In the study a significant improvement in pain intensity was observed within 10 minutes and at all subsequent time points measured throughout the assessment period. Adverse events were
Andrew Dillon, NICE chief executive, said: “Alzheimer’s is a cruel and devastating illness and we realize that today’s announcement will be disappointing to people with Alzheimer’s and those
Ariad will have an equity stake in Bellicum and will receive additional payments based on certain development, regulatory and commercial milestones achieved by the company. Products in this
A company spokesman said that chairman David Kies had resigned for “personal and other reasons” while board member William Crouse did not give a reason for his departure.
This designation brings significant offers benefits to Biovest in its development and marketing of BiovaxID in the European Union. This acceptance follows the previously announced recommendation by the
The trial has been launched in the US to determine the safety, tolerability, and pharmacokinetics of the drug in healthy adult volunteers. The inhaled formulation of ALN-RSV01 used
Azilect is indicated for the treatment of Parkinson's disease both as initial therapy alone and to be added to levodopa later in the disease. The study showed that
The recommendation is subject to the European Commission's approval. The orphan drug designation ensures EU market exclusivity for the drug for a period of ten years following marketing